Targeted Therapy for Stage 4 Cancer: — What You Can Realistically Expect

No targeted therapy is expected to cure a stage 4 cancer. The realistic goal is disease control — slowing or stopping growth and extending the time before progression. For some patients this period is meaningful and sustained. The aim is to keep the cancer stable while preserving quality of life. Any treatment being described as a cure in this setting should be questioned directly with your oncologist.

Eligibility is decided by biomarker testing of your tumour tissue — not by your cancer type or stage alone. The laboratory looks for specific mutations, protein expressions, or other molecular markers that predict whether a targeted drug is likely to work. If testing has not been done, ask your oncologist whether your tumour sample is suitable. Results typically take one to two weeks from when the sample reaches the laboratory.

Chemotherapy damages all rapidly dividing cells throughout the body, which is why it causes hair loss, nausea, and low blood counts. Targeted therapy is designed to act on a specific molecular weakness in the cancer cell and tends to spare more healthy tissue. It comes with its own side effects — commonly skin rashes, diarrhoea, and changes in liver function. These are different from chemotherapy side effects, but they are real and need monitoring.

Side effects vary by drug. Targeted therapies commonly cause skin changes including rash and dry skin, diarrhoea, fatigue, and changes in liver enzyme levels. Some affect blood pressure or heart function and require regular monitoring. Ask your team specifically what to expect with your drug, which symptoms to report immediately, and what blood tests or other checks you will need during treatment. This is a different list from chemotherapy and worth understanding clearly in advance.

There is no fixed answer. The duration varies considerably between patients, cancer types, and which specific drug is used. Resistance — when the cancer adapts and the drug loses its effect — is expected to develop eventually in the majority of cases. ESMO and NCCN guidance treats this as an anticipated event to plan for, not a failure of treatment. Your oncologist can explain what is typically seen with your specific drug and tumour type, while making clear that individual responses cannot be predicted.

When resistance develops, the next step depends on how your cancer has changed. Sometimes a different targeted drug is available that acts on the new mutation. Sometimes a different class of treatment — chemotherapy, immunotherapy, or another approach — becomes the next option. A repeat biopsy or liquid biopsy may be recommended to understand how the tumour has changed. The best time to ask about the second-line plan is now, while you are still responding to the first treatment.

It depends on the drug. Many targeted therapies are oral tablets or capsules taken at home once or twice a day. Others are given as intravenous infusions in a day-care setting. At CION, infusion-based targeted therapy is administered as day care — you come in for the infusion and go home the same day. If your drug is an oral agent, your team will explain exactly how and when to take it, what to do if you miss a dose, and what interactions to avoid.

In some cases, yes. Certain combinations of targeted therapy with chemotherapy are supported by NCCN and ESMO evidence for specific cancer types, and your oncologist will explain whether a combination applies to your situation. Targeted therapy alongside radiotherapy is less common but is used in certain settings. Whether you receive one treatment or a combination depends on your cancer type, your biomarker results, your general fitness, and what the evidence supports for your specific tumour.